Piramal Enterprises: Maintain ‘hold’ with a revised SoTP-based target price of Rs 2,933

By: |
October 12, 2021 12:15 AM

Shareholders of PEL will get 4 equity shares of PPL for every one equity share in PEL, in addition to their existing holding in PEL.

Pirmal Enterprises, non-convertible debuntures, private placement basis., Piramal groupShareholders of PEL will directly own shares in both the listed entities, without any cross-holdings and minority stakes. (File)

Piramal Enterprises (PEL), post DHFL acquisition and integration, has now announced the much-awaited demerger of its pharma business and simplification of the corporate structure. Its board has approved a scheme of arrangement with the objective of transforming the group from a multi-sector conglomerate into two separate sector-focused listed entities in financial services and pharma business. The demerger will:1) strengthen the governance architecture for the businesses with separate dedicated Boards and management teams; 2) create an optimal capital structure for each of the two businesses; 3) empower and enable both the entities to independently pursue their growth strategies (organically and inorganically) with sharper focus; 4) trigger value-unlocking for PEL shareholders. The demerger is subject to shareholders’, creditors’ and regulatory approvals, and the process is expected to take another nine-10 months. We earlier highlighted this as a trigger to further drive up valuation with optimal capital allocation. Maintain ‘hold’ with a revised SoTP-based target price of Rs 2,933 (earlier: Rs 2,797). Effectively leveraging the acquired DHFL network to cross-sell existing retail products will be key going forward. We continue to await visibility on utilisation of unallocated equity (an optional value).

Scheme of arrangement primarily to simplify corporate structure:

Demerge the pharma business and list it separately:

The pharma business will get vertically demerged from PEL and consolidated under Piramal Pharma (PPL). Post the demerger, PPL will be listed on the BSE and the NSE. Two operating subsidiaries, wholly-owned by PPL, will also be amalgamated with PPL to further simplify the pharma corporate structure. They are: 1) Hemmo Pharma Private Limited (focused on development of peptide APIs and manufacturing capabilities), and 2) Convergence Chemical Private Limited (for development, manufacture and sales of speciality fluorochemicals).

Financial services structure: NBFC at holdco level with 100% HFC subsidiary PHL Finvest Private Limited, 100% owned NBFC subsidiary of PEL, will be amalgamated with PEL to create a listed NBFC. The merged housing finance company, post the DHFL acquisition, will remain a wholly-owned subsidiary of PEL.

No change in PEL shareholding structure; 4:1 equity share consideration:

Shareholders of PEL will get 4 equity shares of PPL for every one equity share in PEL, in addition to their existing holding in PEL. Both the companies will be separately listed on the NSE and the BSE.

Shareholders of PEL will directly own shares in both the listed entities, without any cross-holdings and minority stakes.

No change in the shareholding pattern of PEL pursuant to the demerger.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Govt to issue 4 tranches of sovereign gold bonds in H2, to offer 2.5% annual interest to investors
2Foreign portfolio investors turn net sellers of debt so far in October
3Paytm IPO: Paytm may skip a pre-IPO round to fast-track listing